BlueDot

BlueDot (formerly known as BioDiaspora) develops risk assessment technology that enables global leaders to accurately predict and anticipate how emerging infectious disease threats will spread around the world. This capability was scientifically validated during the 2009 H1N1 influenza pandemic and published in the New England Journal of Medicine. BlueDot technology is extensively used by United States Centers for Disease Control, World Health Organization, Public Health Agency of Canada, and other leading institutions that seek to mitigate against the health and economic risks of infectious diseases. BlueDot technology is an advanced web-based enterprise solution that has an integrated live stream of global epidemic intelligence from worldwide infectious disease surveillance systems and contextualizes these threats by integrating an extensive number of datasets pertaining to human and animal populations, climate, health system environments, economic conditions, and many other factors. BlueDot users can conduct in-depth analysis of the continuously evolving architecture of the global airline transportation network and the origins, travel routes, and destinations of more than two billion passengers who pass through it every year.